NCT06614231View on ClinicalTrials.gov

Neoajuvant Tislelizumab Combined with Chemotherapy for Initially Unresectable Stage IIIA/N2 Non-small Cell Lung Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

September 20, 2024

Primary Completion Date

September 8, 2028

Study Completion Date

September 8, 2028

Conditions
NSCLC, Stage IIIANSCLC (non-small Cell Lung Cancer)
Interventions
DRUG

Tislelizumab Combined With Chemotherapy

Tislelizumab 200mg Q3W，Platinum-containing dual drug chemotherapy

All Listed Sponsors
lead

Sun Yat-sen University

OTHER

NCT06614231 - Neoajuvant Tislelizumab Combined with Chemotherapy for Initially Unresectable Stage IIIA/N2 Non-small Cell Lung Cancer | Biotech Hunter | Biotech Hunter